Literature DB >> 3037535

Down-regulation of rat kidney calcitonin receptors by salmon calcitonin infusion evidenced by autoradiography.

Z Bouizar, W H Rostène, G Milhaud.   

Abstract

In treating age-related osteoporosis and Paget disease of bone, it is of major importance to avoid an escape phenomenon that would reduce effectiveness of the treatment. The factors involved in the loss of therapeutic efficacy with administration of large pharmacological doses of the hormone require special consideration. Down-regulation of the hormone receptors could account for the escape phenomenon. Specific binding sites for salmon calcitonin (sCT) were characterized and localized by autoradiography on rat kidney sections incubated with 125I-labeled sCT. Autoradiograms demonstrated a heterogenous distribution of 125I-labeled sCT binding sites in the kidney, with high densities in both the superficial layer of the cortex and the outer medulla. Infusion of different doses of unlabeled sCT by means of Alzet minipumps for 7 days produced rapid changes in plasma calcium, phosphate, and magnesium levels, which were no longer observed after 2 or 6 days of treatment. Besides, infusion of high doses of sCT induced down-regulation of renal sCT binding sites located mainly in the medulla, where calcitonin (CT) has been shown to exert its physiological effects on water and ion reabsorption. These data suggest that the resistance to high doses of sCT often observed during long-term treatment of patients may be the consequence of not only bone-cell desensitization but also down-regulation of CT-sensitive kidney receptor sites.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3037535      PMCID: PMC298806          DOI: 10.1073/pnas.84.15.5125

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  16 in total

Review 1.  Calcitonin binding sites in bone: relationships to biological response and "escape".

Authors:  A H Tashjian; D R Wright; J L Ivey; A Pont
Journal:  Recent Prog Horm Res       Date:  1978

2.  Kinetics of calcitonin receptor internalization in lung cancer (BEN) and osteogenic sarcoma (UMR 106-06) cells.

Authors:  D M Findlay; T J Martin
Journal:  J Bone Miner Res       Date:  1986-06       Impact factor: 6.741

3.  Characterization and quantitative topographical distribution of salmon calcitonin-binding sites in rat kidney sections.

Authors:  Z Bouizar; W H Rostène; M S Moukhtar; G Milhaud
Journal:  FEBS Lett       Date:  1986-02-03       Impact factor: 4.124

4.  Quantitative aspects of the insulin-receptor interaction in liver plasma membranes.

Authors:  C R Kahn; P Freychet; J Roth; D M Neville
Journal:  J Biol Chem       Date:  1974-04-10       Impact factor: 5.157

5.  Loss of calcemic effects of calcitonin and parathyroid hormone infused continuously into rats using the Alzet osmotic minipump.

Authors:  J F Obie; C W Cooper
Journal:  J Pharmacol Exp Ther       Date:  1979-06       Impact factor: 4.030

6.  Calcitonin receptors of kidney and bone.

Authors:  S J Marx; C J Woodward; G D Aurbach
Journal:  Science       Date:  1972-12-01       Impact factor: 47.728

7.  An evaluation of antibodies and clinical resistance to salmon calcitonin.

Authors:  F R Singer; J P Aldred; R M Neer; S M Krane; J T Potts; K J Bloch
Journal:  J Clin Invest       Date:  1972-09       Impact factor: 14.808

8.  ADH-like effects of calcitonin on electrolyte transport by Henle's loop of rat kidney.

Authors:  J M Elalouf; N Roinel; C de Rouffignac
Journal:  Am J Physiol       Date:  1984-02

Review 9.  Sites of hormone action in the mammalian nephron.

Authors:  F Morel
Journal:  Am J Physiol       Date:  1981-03

10.  Effect of calcitonin on calcium and magnesium transport in rat nephron.

Authors:  G A Quamme
Journal:  Am J Physiol       Date:  1980-06
View more
  16 in total

1.  Differential short-term desensitization to vasopressin, isoproterenol, glucagon, parathyroid hormone and calcitonin in the thick ascending limb of rat kidney.

Authors:  I Dublineau; P Pradelles; C de Rouffignac; J M Elalouf
Journal:  Pflugers Arch       Date:  1992-01       Impact factor: 3.657

Review 2.  Treatment of patients with Paget's disease of bone.

Authors:  C Roux; M Dougados
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

3.  Enhancement of 1,25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis by calcitonin.

Authors:  Bryan R Becklund; Donald W Hansen; Hector F Deluca
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-12       Impact factor: 11.205

4.  Salmon calcitonin reduces food intake through changes in meal sizes in male rhesus monkeys.

Authors:  Nicholas T Bello; Matthew H Kemm; Timothy H Moran
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-05-14       Impact factor: 3.619

5.  Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.

Authors:  N M Nielsen; P von der Recke; M A Hansen; K Overgaard; C Christiansen
Journal:  Calcif Tissue Int       Date:  1994-07       Impact factor: 4.333

6.  Hypocalcemic effect of salmon calcitonin following single and repeated nasal and intravenous administration in young rabbits.

Authors:  N G Schipper; S G Romeijn; J Verhoef; F W Merkus
Journal:  Calcif Tissue Int       Date:  1994-01       Impact factor: 4.333

7.  Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.

Authors:  K Overgaard
Journal:  Calcif Tissue Int       Date:  1994-08       Impact factor: 4.333

8.  Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation.

Authors:  J Y Reginster; S Gaspar; R Deroisy; B Zegels; P Franchimont
Journal:  Osteoporos Int       Date:  1993-09       Impact factor: 4.507

9.  Endogenous production of specific antibodies does not decrease hypocalcemic response to calcitonin in young rabbits.

Authors:  J Y Reginster; M Azria; S Gaspar; M Bleicher; N Franchimont; M Behhar; A Albert; P Franchimont
Journal:  Calcif Tissue Int       Date:  1992-06       Impact factor: 4.333

10.  Long-term treatment of established osteoporosis with intranasal calcitonin.

Authors:  K Overgaard; C Christiansen
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.